Patents by Inventor Guenter Hoelzemann

Guenter Hoelzemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Macrocycles as kinase inhibitors
    Patent number: 9861635
    Abstract: Compounds of the formula I in which X, Y, Q1, M, Q2 and B have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: January 9, 2018
    Assignee: Merck Patent Gmbh
    Inventors: Guenter Hoelzemann, Dieter Dorsch, Ansgar Wegener, Oliver Poeschke, Michael Busch
  • Triazolo[4,5-d]pyrimidine derivatives
    Patent number: 9855268
    Abstract: Compounds of the formula I in which R1 and R2 have the meanings indicated in claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: January 2, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Dieter Dorsch, Guenter Hoelzemann, Michel Calderini, Ansgar Wegener, Oliver Poeschke
  • Imidazopyrimidine derivatives
    Patent number: 9617266
    Abstract: Compounds of the formula I in which X, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: April 11, 2017
    Assignee: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Dieter Dorsch, Ansgar Wegener, Oliver Poeschke, Michael Busch, Jeyaprakashnarayanan Seenisamy
  • Triazolo[4,5-d]pyrimidine derivatives
    Patent number: 9409914
    Abstract: Compounds of the formula I in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: August 9, 2016
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Guenter Hoelzemann, Kai Schiemann, Ansgar Wegener
  • MACROCYCLES AS KINASE INHIBITORS
    Publication number: 20160166574
    Abstract: Compounds of the formula I in which X, Y, Q1, M, Q2 and B have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: April 9, 2014
    Publication date: June 16, 2016
    Applicant: Merck Patent Gmbh
    Inventors: Guenter HOELZEMANN, Dieter DORSCH, Ansgar WEGENER, Oliver POESCHKE, Michael BUSCH
  • Pyridine-and pyrazine derivatives
    Patent number: 9273029
    Abstract: Compounds of the formula (I) in which R, R1 and X have the meanings indicated in claim 1, are inhibitors of TBK1 and IKK? and can be employed, inter alia, for the treatment of cancer and inflammatory diseases
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: March 1, 2016
    Assignee: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Hans-Michael Eggenweiler, Srinivasa R. Karra
  • Triazolo[4,5-d]pyrimidine derivatives
    Publication number: 20160015712
    Abstract: Compounds of the formula I in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: February 10, 2014
    Publication date: January 21, 2016
    Applicant: MERCK PATENT GMBH
    Inventors: Dieter DORSCH, Guenter HOELZEMANN, Michel CALDERINI, Ansgar WEGENER, Oliver POESCHKE
  • IMIDAZOPYRIMIDINE DERIVATIVES
    Publication number: 20160002242
    Abstract: Compounds of the formula I in which X, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: February 11, 2014
    Publication date: January 7, 2016
    Applicant: Merck Patent GmbH
    Inventors: Guenter HOELZEMANN, Dieter DORSCH, Ansgar WEGENER, Oliver POESCHKE, Michael BUSCH, Jeyaprakashnarayanan SEENISAMY
  • 3-Cyanoaryl-1H-pyrrolo[2,3-B] pyridine derivatives
    Patent number: 9102675
    Abstract: Compounds of the formula (I) in which R1, R2, X and Y have the meanings indicated in claim 1, are inhibitors of TBK1 and IKK? and can be employed, inter alia, for the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: August 11, 2015
    Assignee: MERCK PATENT GMBH
    Inventors: Dieter Dorsch, Guenter Hoelzemann, Hans-Michael Eggenweiler, Paul Czodrowski
  • Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith
    Patent number: 9051318
    Abstract: The present invention relates to novel pyrido[2,3-b]pyrazine compounds of formula (I): and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: June 9, 2015
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Alfred Jonczyk, Guenter Hoelzemann, Christiane Amendt, Frank Zenke
  • Bipyridyl derivatives
    Patent number: 9051307
    Abstract: The present invention relates to novel bipyridyl derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: June 9, 2015
    Assignee: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Dieter Dorsch, Alfred Jonczyk, Christiane Amendt, Frank Zenke
  • Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives
    Patent number: 9045493
    Abstract: Compounds of the formula I are inhibitors of TBK1 and IKK? and can be employed, inter alia, for the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: June 2, 2015
    Assignee: MERCK PATENT GMBH
    Inventors: Hans Michael Eggenweiler, Guenter Hoelzemann, Dieter Dorsch
  • Benzonitrile derivatives as kinase inhibitors
    Patent number: 8969335
    Abstract: Compounds of the formula I, in which R1, R2, X and Y have the meanings indicated in Claim 1, are inhibitors of TBK1 and IKK? and can be employed, inter alia, for the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: March 3, 2015
    Assignee: MERCK PATENT GmbH
    Inventors: Guenter Hoelzemann, Dieter Dorsch, Hans-Michael Eggenweiler
  • TRIAZOLOPYRAZINE DERIVATIVES
    Publication number: 20150051202
    Abstract: Compounds of the formula I in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: February 14, 2013
    Publication date: February 19, 2015
    Applicant: Merck Patent GmbH
    Inventors: Kai Schiemann, Carl Deutsch, Guenter Hoelzemann, Daniel Kuhn, Ansgar Wegener, Dominique Swinnen, Horacio Comas
  • Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives
    Publication number: 20150005284
    Abstract: Compounds of the formula I in which R1, R2 and X have the meanings indicated in Claim 1, are inhibitors of TBK1 and IKK? and can be employed, inter alia, for the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: January 3, 2013
    Publication date: January 1, 2015
    Applicant: Merck Patent GmbH
    Inventors: Hans Michael Eggenweiler, Guenter Hoelzemann, Dieter Dorsch
  • TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES
    Publication number: 20140378431
    Abstract: Compounds of the formula I in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: December 21, 2012
    Publication date: December 25, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Dieter Dorsch, Guenter Hoelzemann, Kai Schiemann, Ansgar Wegener
  • Hetaryl-[1,8]naphthyridine derivatives
    Patent number: 8912216
    Abstract: Novel hetaryl-[1,8]naphthyridine derivatives of formula (I) wherein R1, R2, W1, W3, W5 and W6 have the meaning according to claim 1, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: December 16, 2014
    Assignee: Merck Patent GmbH
    Inventors: Alfred Jonczyk, Dieter Dorsch, Guenter Hoelzemann, Christiane Amendt, Frank Zenke
  • BIPYRIDYL DERIVATIVES
    Publication number: 20140336201
    Abstract: The present invention relates to novel bipyridyl derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.
    Type: Application
    Filed: July 29, 2014
    Publication date: November 13, 2014
    Inventors: Guenter HOELZEMANN, Dieter DORSCH, Alfred JONCZYK, Christiane AMENDT, Frank ZENKE
  • 3-CYANOARYL-1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES
    Publication number: 20140323481
    Abstract: Compounds of the formula (I) in which R1, R2, X and Y have the meanings indicated in claim 1, are inhibitors of TBK1 and IKK? and can be employed, inter alia, for the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: October 30, 2012
    Publication date: October 30, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Dieter Dorsch, Guenter Hoelzemann, Hans-Michael Eggenweiler, Paul Czodrowski
  • Bipyridyl derivatives
    Patent number: 8846931
    Abstract: The present invention relates to novel bipyridyl derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: September 30, 2014
    Assignee: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Dieter Dorsch, Alfred Jonczyk, Christiane Amendt, Frank Zenke